SEC Form 4 · accession 0001209191-19-005225
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason W. Radford
Officer — Chief Legal Officer
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Jan 22, 2019 | S | 1,538 | $70.9716 | D | 32,751 | D | |
| Common StockF1,F2,F5,F4 | Jan 22, 2019 | S | 1,425 | $71.9502 | D | 31,326 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 15, 2018.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $70.52 to $71.48.
- F4Includes an aggregate of 24,447 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F5Represents weighted average sale price. Actual sale prices ranged from $71.62 to $72.02.